KAZIA THERAPEUTICS LTD (KZIA)
About KAZIA THERAPEUTICS LTD
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $125.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $125.6M
- Shares outstanding
- 10.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 6, 1999
Kazia Therapeutics Ltd (KZIA) Stock Price
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KAZIA THERAPEUTICS LTD.
Write a review
News about KAZIA THERAPEUTICS LTD
News & sentiment via Polygon.io
Kazia Therapeutics Ltd: frequently asked questions
Is Kazia Therapeutics Ltd an American company?
Kazia Therapeutics Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Kazia Therapeutics Ltd publicly traded?
Yes — Kazia Therapeutics Ltd is a publicly traded company. Its stock trades under the ticker symbol KZIA on the NASDAQ.
What does Kazia Therapeutics Ltd do?
Kazia Therapeutics Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
